Literature DB >> 15777982

Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer.

Jun Araki1, Isamu Okamoto, Ryuichiro Suto, Yasuko Ichikawa, Ji-ichiro Sasaki.   

Abstract

Gefitinib (Iressa, ZD1839) is an orally active inhibitor selective for the epidermal growth factor receptor tyrosine kinase and has shown promise in the treatment of non-small cell lung cancer (NSCLC). There has been no report to date of the effect of gefitinib treatment in patients with small-cell lung cancer (SCLC). Here we report a case of metastatic SCLC that was successfully treated with gefitinib. This case is the first reported of objective clinical response after gefitinib treatment in a patient with SCLC. Our report suggests that treatment with gefitinib is a novel option for a subset of patients with SCLC.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15777982     DOI： 10.1016/j.lungcan.2004.10.012

Source DB:  PubMed          Journal:  Lung Cancer        ISSN： 0169-5002            Impact factor:   5.705


  14 in total

Review 1.  Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin.

Authors:  Matthew G Oser; Matthew J Niederst; Lecia V Sequist; Jeffrey A Engelman
Journal:  Lancet Oncol       Date:  2015-04       Impact factor: 41.316

Review 2.  Biopsy and re-biopsy in lung cancer: the oncologist requests and the role of endobronchial ultrasounds transbronchial needle aspiration.

Authors:  Alessandro Tuzi; Elena Bolzacchini; Matteo B Suter; Alice Giaquinto; Antonio Passaro; Stefania Gobba; Ilaria Vallini; Graziella Pinotti
Journal:  J Thorac Dis       Date:  2017-05       Impact factor: 2.895

3.  Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

Authors:  Neal I Lindeman; Philip T Cagle; Mary Beth Beasley; Dhananjay Arun Chitale; Sanja Dacic; Giuseppe Giaccone; Robert Brian Jenkins; David J Kwiatkowski; Juan-Sebastian Saldivar; Jeremy Squire; Erik Thunnissen; Marc Ladanyi
Journal:  J Thorac Oncol       Date:  2013-07       Impact factor: 15.609

4.  Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

Authors:  Neal I Lindeman; Philip T Cagle; Mary Beth Beasley; Dhananjay Arun Chitale; Sanja Dacic; Giuseppe Giaccone; Robert Brian Jenkins; David J Kwiatkowski; Juan-Sebastian Saldivar; Jeremy Squire; Erik Thunnissen; Marc Ladanyi
Journal:  Arch Pathol Lab Med       Date:  2013-04-03       Impact factor: 5.534

5.  Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation.

Authors:  Rintaro Noro; Akihiko Gemma; Seiji Kosaihira; Yutaka Kokubo; Mingwei Chen; Masahiro Seike; Kiyoko Kataoka; Kuniko Matsuda; Tetsuya Okano; Yuji Minegishi; Akinobu Yoshimura; Shoji Kudoh
Journal:  BMC Cancer       Date:  2006-12-06       Impact factor: 4.430

6.  Large-cell neuroendocrine carcinoma of lung with epidermal growth factor receptor (EGFR) gene mutation and co-expression of adenocarcinoma markers: a case report and review of the literature.

Authors:  Yasuhiro Sakai; Takashi Yamasaki; Yoshito Kusakabe; Daisuke Kasai; Yoshikazu Kotani; Yoshihiro Nishimura; Tomoo Itoh
Journal:  Multidiscip Respir Med       Date:  2013-07-18

7.  Tyrosine Kinase Inhibitors in EGFR-Mutated Large-Cell Neuroendocrine Carcinoma of the Lung? A Case Report.

Authors:  Francesca Aroldi; Paola Bertocchi; Fausto Meriggi; Chiara Abeni; Chiara Ogliosi; Luigina Rota; Claudia Zambelli; Claudio Bnà; Alberto Zaniboni
Journal:  Case Rep Oncol       Date:  2014-07-16

8.  Small-cell lung cancer with a rare epidermal growth factor receptor gene mutation showing "wax-and-wane" transformation.

Authors:  Yusuke Takagi; Yoshiro Nakahara; Yukio Hosomi; Tsunekazu Hishima
Journal:  BMC Cancer       Date:  2013-11-07       Impact factor: 4.430

9.  EGFR, KRAS, BRAF, PTEN, and PIK3CA mutation in plasma of small cell lung cancer patients.

Authors:  Hong-Yang Lu; Jing Qin; Na Han; Lei Lei; Fajun Xie; Chenghui Li
Journal:  Onco Targets Ther       Date:  2018-04-20       Impact factor: 4.147

Review 10.  [Advances in the Transformation to Small Cell Lung Cancer from Non-small Cell Lung Cancer Following Acquired Drug-resistance to EGFR Tyrosine Kinase Inhibitors].

Authors:  Wenqiu Zhang; Yongqi Li; Di Wu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2017-10-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.